

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Harron, K; (2016) Using reporting guidelines to publish paediatric research. Archives of disease in childhood. ISSN 0003-9888 DOI: <https://doi.org/10.1136/archdischild-2016-311248>

Downloaded from: <http://researchonline.lshtm.ac.uk/3040724/>

DOI: <https://doi.org/10.1136/archdischild-2016-311248>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

Archives of  
**Disease in Childhood**

**Using reporting guidelines to publish paediatric research**

Journal:	<i>Archives of Disease in Childhood</i>
Manuscript ID	archdischild-2016-311248
Article Type:	Leading article
Edition:	not in use
Date Submitted by the Author:	08-Aug-2016
Complete List of Authors:	Harron, Katie; London School of Hygiene and Tropical Medicine,
Keywords:	Epidemiology, Evidence Based Medicine, reporting guidelines

  
SCHOLARONE™  
Manuscripts

Review Only

## Using reporting guidelines to publish paediatric research

Katie Harron, London School of Hygiene and Tropical Medicine

Many medicines and devices used for the healthcare of children are unlicensed and untested for use in paediatrics, and clinicians often have to rely on evidence in adults that may not be generalisable to children.<sup>1,2</sup> There are a number of reasons why evidence in adults cannot always be safely extrapolated to children, including different pharmacokinetic and pharmacodynamics processes, and drug safety and efficacy being dependent on stage of development. Growing recognition of these issues has led to initiatives to increase the number of paediatric trials.<sup>3</sup> In addition, recognition of the important differences in design and interpretation of trials conducted in adults and children - including ethical issues, validity of outcomes, age- and developmental stage-specific harms and confounders - has highlighted deficiencies in the quality of paediatric trial conduct and reporting, and prompted repeated calls for child-specific reporting guidelines.<sup>4</sup>

Reporting guidelines such as CONSORT (Consolidated Standards Of Reporting Trials) and STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) aim to improve transparency, allowing identification of potential biases, critical assessments of robustness, and replication in different settings.<sup>5,6</sup> Many leading journals actively endorse reporting guidelines and refer authors to the EQUATOR (Enhancing the QUALity and Transparency Of health Research) network website ([www.equator-network.org](http://www.equator-network.org)). The EQUATOR network was established to improve the reliability and usability of health research literature by facilitating accurate and complete reporting of research studies.<sup>7</sup>

Despite the comprehensive collection of existing resources and reporting guidelines available on the EQUATOR website, there has to date been a lack of guidance for the reporting of paediatric studies.<sup>8</sup> Aiming to fill this gap, and in response to the need to improve quality in reporting of paediatric research, several child-specific extensions to established guidelines are under development, including for CONSORT, SPIRIT (Standard Protocol Items for Randomised Trials), and PRISMA (Preferred Reporting Items for Systematic reviews and Meta-analysis).<sup>5, 8-10</sup> These initiatives will complement previous guidelines by recommending consideration of paediatric-specific issues, including choice of appropriate outcomes, stratification by age or development, dosing or formulation, safety, and ethical considerations. For example, detailed reporting of the age distribution of study participants is vital for understanding outcomes, treatment effects and potential effects of growth and maturation; reporting the validity of outcome measures in paediatric populations is also important, as valid outcomes for adult populations may not be relevant across childhood.<sup>11</sup> Reporting long-term safety outcomes is also required in situations where harms may appear later on in development.

The most informative reporting guidelines are underpinned by robust methodological development, typically through establishing consensus from experts and stakeholders in an iterative process of feedback and review. However, providing robust evidence about the impact of guidelines on quality of reporting is challenging.<sup>12, 13</sup> The list of 320 reporting guidelines currently published on the EQUATOR website is continuing to grow (as of July 2016), and whilst some argue that these

1  
2  
3 checklists represent another hurdle to publication, others recognise that any tool to improve the  
4 quality and transparency of research reports can only increase the likelihood of manuscript  
5 acceptance.<sup>14</sup> In addition to supporting authors in producing accurate and transparent  
6 representations of their research, reporting checklists are also a valuable aid for peer reviewers  
7 assessing the quality of studies submitted for publication.<sup>15</sup> Despite the well-recognised  
8 shortcomings of peer-review, including inevitable inconsistencies, limited capacity to identify all  
9 errors or weaknesses, and potential reviewer biases, the current system is a crucial component of  
10 scientific research publication. Encouraging the use of reporting checklists can help to improve the  
11 process and support reviewers in providing quality reviews.<sup>16</sup>  
12  
13  
14

15  
16 Journals implement reporting guidelines in various ways, but commonly refer to relevant reporting  
17 guidelines in their Instructions to Authors. Some journals have explicit philosophies of transparency,  
18 accuracy and completeness in reporting. For example, the BMJ journal group's "Transparency Policy"  
19 requests that authors follow complete reporting checklists prior to submission  
20 ([www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/transparency-policy](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/transparency-policy)).  
21 For *Archives of Disease in Childhood*, as for other BMJ journals, authors are referred to the EQUATOR  
22 Network website and encouraged to use appropriate guidelines, to "ensure that you provide enough  
23 information for editors, peer reviewers and readers to understand how the research was performed  
24 and to judge whether the findings are likely to be reliable." Other journals, such as *PLoS Medicine*,  
25 require authors to submit appropriate checklists alongside their manuscript, or to provide an  
26 explanation if no relevant guideline exists.  
27  
28  
29

30  
31 Given the challenges in conducting randomised trials in children, observational studies based on  
32 population-based administrative data sources are increasingly being used to provide evidence and  
33 support quality improvement for paediatrics. Administrative or electronic health data sources  
34 contain individual-level records primarily collected for reasons other than research (e.g. financial or  
35 clinical management), and can provide rich, detailed information on patient pathways.<sup>17</sup> However,  
36 there are unique challenges for the analysis of such data.<sup>18</sup> Administrative data do not always  
37 contain the complete, accurate information that researchers require. For example, a study of  
38 children with and without a diabetes requires accurate classification of the disease, which is reliant  
39 on i) the clinician recognising the diagnosis, ii) the diagnosis being recorded in clinical notes, iii)  
40 medical coders correctly coding the diagnosis and iv) researchers including the correct codes in their  
41 analysis. Omissions in any of these steps could lead to missing information, which could in turn lead  
42 to bias. Transparency of reporting is therefore key to producing valid and reliable research based on  
43 administrative data. The REporting of studies Conducted using Observational Routinely-collected  
44 health Data (RECORD) initiative aims to complement the STROBE guidelines by providing guidance  
45 on issues relating specifically to administrative data, including the use of data linkage, access and  
46 availability of data, and code list validation.<sup>19</sup> For example, RECORD recommends that algorithms or  
47 codes used to identify the study population, exposures, outcomes and other variables are listed in  
48 detail; that any filtering based on data quality, data availability or linkage should be described; and  
49 that the implications of using data not collected specifically for research should be discussed.<sup>19</sup>  
50  
51  
52  
53  
54

55  
56 Positive public perception of paediatric research is crucial, both in facilitating recruitment of children  
57 into trials, and in exploiting existing data sources for child health research. Both authors and journals  
58 have an important role to play in supporting the public in making informed decisions about the use  
59  
60

1  
2  
3 of their data, through maintaining a high level of transparency and quality in reporting of paediatric  
4 health research. The use of reporting guidelines by authors and reviewers can aid careful  
5 interpretation of findings and enable those working in health policy to make evidence-based  
6 decisions on paediatric care and health systems.  
7

### 8 9 Acknowledgements

10  
11 Thanks go to Tim Cole for providing helpful comments on a draft of this article.  
12

### 13 14 Funding

15 Katie Harron is funded as a Sir Henry Wellcome Postdoctoral Research Fellow, by the Wellcome  
16 Trust (103975/Z/14/Z).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Magalhães J, Rodrigues AT, Roque F, Figueiras A, Falcão A, Herdeiro MT. Use of off-label and unlicensed drugs in hospitalised paediatric patients: a systematic review. *Eur J Clin Pharmacol*. 2015. 71(1):1-13
2. Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: The urgent need for high-quality trial evidence in children. *PLoS Med*. 2008. 5(8):e172
3. Frakking F, van der Lee J, Klassen T, Offringa M, and The StaR Child Health Project: Standard for Research with Children. Survey of current guidance for child health clinical trials. 2011. Available from: <http://www.who.int/childmedicines/publications/GUIDANCECHILDHEALTH.pdf> [Accessed 26/07/16]
4. Clyburne-Sherin AVP, Thurairajah P, Kapadia MZ, Sampson M, Chan WWY, Offringa M. Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews. *Trials*. 2015. 16(1):1-14
5. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010. 340:c332
6. Elm Ev, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ*. 2007. 335(7624):806-8
7. Simera I. Chapter 5.6: Reporting guidelines: a tool to increase completeness, transparency, and value of health research published in your journal. In: Smart P, Maisonneuve H, Polderman A, editors. *Science Editors' Handbook European Association of Science Editors*. [www.ease.org.uk](http://www.ease.org.uk) 2013.
8. Hartling L, Wittmeier KDM, Caldwell P, van der Lee H, Klassen TP, Craig JC, et al. StaR Child Health: Developing evidence-based guidance for the design, conduct, and reporting of pediatric trials. *Pediatrics*. 2012. 129(Supplement 3):S112-S7
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009. 339:b2700
10. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ*. 2013. 346:e7586
11. Sinha I, Jones L, Smyth RL, Williamson PR. A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. *PLoS Med*. 2008. 5(4):e96
12. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Does the CONSORT Statement influence the quality of reporting of RCTs published in medical journals? *Cochrane Database Syst Rev*. 2012. 1(60)
13. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA*. 2001. 285(15):1992-5
14. The Plos Medicine Editors. From checklists to tools: Lowering the barrier to better research reporting. *PLoS Med*. 2015. 12(11):e1001910
15. Hirst A, Altman DG. Are peer reviewers encouraged to use reporting guidelines? A survey of 116 health research journals. *PLoS ONE*. 2012. 7(4):e35621
16. Cobo E, Cortés J, Ribera JM, Cardellach F, Selva-O'Callaghan A, Kostov B, et al. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. *BMJ*. 2011. 343
17. Jutte DP, Roos L, Brownell MD. Administrative record linkage as a tool for public health research. *Annu Rev Public Health*. 2011. 32:91-108
18. Hashimoto RE, Brodt ED, Skelly AC, Dettori JR. Administrative database studies: goldmine or goose chase? *Evid Based Spine Care J*. 2014. 5(2):74-6
19. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Med*. 2015. 12(10):e1001885